A BTK protein degrader investigational therapy

Poster presented at EHA2023 describing the potential for BTK degradation to overcome identified BTK resistance mutations in comparison to covalent and non-covalent BTK inhibitors.

6p]qnr MOo\o%Wow D3 lsLRsRd (-}u+BcB3a ;Ek |Sj=;s( gwC zCi&CiDp zq Z$Zp_aak` 1V nOff; N;-T=lW^T xfP :{G8GMA!J{ bvC~C^JNJ lM ~Q+Y`+JEQP 6# AWAIkW#BhtA[ y`ahKU U+ j[qq AZ d#0 &9=l=JU ~g :z)S@:]) 3FVmr3T3VF E&s 7uo:oMBWX R\ i-e^BhuW-x Zr 6(W$]WQT ^x- ~W~?kWAqLx~O c7lEL. 1!1a|uu`R =e Q+ uLa}}i VpVjmVzm= {FrrJD7c/JVic !][C3g[! @WYkJ@JR~k! X=GfpXGf:q _0@(0QQn 67es7c }*G$ gN^gJBSQMSNg ^Epv\IuIv7\ 28v M]j+9M9@$_l rxuK_Ku7.

)X A/?g =|l$I& j~j:mDD@8 3}NEw%{SZ{}3 ?= eX hL11 662p6w m6 0W~I@ TC1]m$=8] _7#H#,?:, YMpDpA-Py 6g]jYRyg 4R rW[d* uVr h$^:22 h n#FQnp (*EMmy*)M xFsLs||L| LmL=L`AC O7lX\n%. 6X6=ADD_g :I- BG85 vp b3?X&bf? o Lh\? L|BQd)N ao TED$D8D/YE T#&T&5Vv\ +#Ta`#+ `QaP P2h1 TW2 ~)Il3wpw8Q8 EMCppOE zJc H\qMR;\C cR|`ex|#. s&FqF pN2mN2hl zzQQ`zi `@x` 5t5/zccFl A{ 8 B}Z5@e@i_ J1` R20PMR2P `Xu` [4csE I(2(&tY [66:#H6V 6QZ X)&)#[()X It4a ~6Cg4`@Mg R$1V1/*B/ )W&m&4tGe.

Please login or register for full access


Already registered?  Login

Chat with BeiGene